Azedra (iobenguane I 131) in patients with malignant, recurrent and/or unresectable pheochromocytoma or paraganglioma (PPGL): Updated efficacy and safety results from a multi-center, open-label, pivotal phase 2 study.

Daniel Pryma; Bennett Chin; Richard Noto; Joseph Dillon; Lilja Solnes; Theresa White; Nancy Stambler; Tess Lin; Vincent A. DiPippo; Jessica Donato Jensen; Syed Mahmood; Vivien Wong; Camilo Jimenez

doi:10.1200/jco.2018.36.15_suppl.4005

Azedra (iobenguane I 131) in patients with malignant, recurrent and/or unresectable pheochromocytoma or paraganglioma (PPGL): Updated efficacy and safety results from a multi-center, open-label, pivotal phase 2 study.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.4005 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 4005-4005 ◽

Cited By ~ 1

Author(s):

Daniel Pryma ◽

Bennett Chin ◽

Richard Noto ◽

Joseph Dillon ◽

Lilja Solnes ◽

...

Keyword(s):

Phase 2 ◽

Efficacy And Safety ◽

Open Label ◽

Pivotal Phase ◽

Phase 2 Study

Download Full-text

Faculty Opinions recommendation of An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718028323.793480222 ◽

2013 ◽

Author(s):

Richard Riedel

Keyword(s):

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Phase 2 ◽

Efficacy And Safety ◽

Open Label ◽

Phase 2 Study ◽

Open Label Phase ◽

Metastatic Soft Tissue Sarcoma ◽

Previously Treated

Download Full-text

Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study

The Lancet Oncology ◽

10.1016/s1470-2045(21)00056-5 ◽

2021 ◽

Author(s):

Robert L Coleman ◽

Domenica Lorusso ◽

Christine Gennigens ◽

Antonio González-Martín ◽

Leslie Randall ◽

...

Keyword(s):

Cervical Cancer ◽

Phase 2 ◽

Efficacy And Safety ◽

Open Label ◽

Phase 2 Study ◽

Previously Treated

Download Full-text

UMBRALISIB MONOTHERAPY DEMONSTRATES EFFICACY AND SAFETY IN PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA: A MULTICENTER, OPEN-LABEL, REGISTRATION DIRECTED PHASE 2 STUDY

Hematological Oncology ◽

10.1002/hon.139_2629 ◽

2019 ◽

Vol 37 ◽

pp. 182-183 ◽

Cited By ~ 2

Author(s):

P. Zinzani ◽

F. Samaniego ◽

W. Jurczak ◽

E. Lech-Maranda ◽

N. Ghosh ◽

...

Keyword(s):

Marginal Zone ◽

Marginal Zone Lymphoma ◽

Phase 2 ◽

Efficacy And Safety ◽

Open Label ◽

Phase 2 Study

Download Full-text

PD31-06 UPDATED LONG-TERM SURVIVAL AND SAFETY FROM A MULTI-CENTER, OPEN-LABEL, PIVOTAL PHASE 2 STUDY OF AZEDRA® IN PATIENTS WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC PHEOCHROMOCYTOMA OR PARAGANGLIOMA

The Journal of Urology ◽

10.1097/ju.0000000000000895.06 ◽

2020 ◽

Vol 203 ◽

pp. e632

Author(s):

Camilo Jimenez* ◽

Bennett B. Chin ◽

Richard B. Noto ◽

Joseph S. Dillon ◽

Lilja Solnes ◽

...

Keyword(s):

Locally Advanced ◽

Phase 2 ◽

Open Label ◽

Pivotal Phase ◽

Term Survival ◽

Long Term Survival ◽

Phase 2 Study

Download Full-text

Abstract P6-20-07: Efficacy and safety of CB-839, a small molecule inhibitor of glutaminase, in combination with paclitaxel in patients with advanced triple negative breast cancer (TNBC): Initial findings from a multicenter, open-label phase 2 study

10.1158/1538-7445.sabcs18-p6-20-07 ◽

2019 ◽

Author(s):

G Vidal ◽

K Kalinsky ◽

E Stringer-Reasor ◽

F Lynce ◽

J Cole ◽

...

Keyword(s):

Breast Cancer ◽

Small Molecule ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Phase 2 ◽

Efficacy And Safety ◽

Open Label ◽

Molecule Inhibitor ◽

Phase 2 Study ◽

Open Label Phase

Download Full-text

Efficacy and safety of long-acting pasireotide in Japanese patients with acromegaly or pituitary gigantism: results from a multicenter, open-label, randomized, phase 2 study

Endocrine Journal ◽

10.1507/endocrj.ej16-0624 ◽

2017 ◽

Vol 64 (7) ◽

pp. 735-747 ◽

Cited By ~ 5

Author(s):

Shigeyuki Tahara ◽

Mami Murakami ◽

Tomomi Kaneko ◽

Akira Shimatsu

Keyword(s):

Japanese Patients ◽

Phase 2 ◽

Efficacy And Safety ◽

Open Label ◽

Phase 2 Study ◽

Long Acting ◽

Randomized Phase 2

Download Full-text

EPSTEIN‐BARR VIRUS‐DRIVEN DISEASES: A MULTINATIONAL, MULTICOHORT, OPEN‐LABEL PHASE 2 STUDY TO ASSESS THE EFFICACY AND SAFETY OF TABELECLEUCEL USING AN ADAPTIVE STUDY DESIGN

Hematological Oncology ◽

10.1002/hon.170_2880 ◽

2021 ◽

Vol 39 (S2) ◽

Author(s):

S. Choquet ◽

J. A. Pérez‐Simón ◽

N. Worel ◽

S. Chaganti ◽

R. Dinavahi ◽

...

Keyword(s):

Study Design ◽

Epstein Barr Virus ◽

Phase 2 ◽

Efficacy And Safety ◽

Open Label ◽

Barr Virus ◽

Phase 2 Study ◽

Open Label Phase ◽

Epstein Barr ◽

Adaptive Study Design

Download Full-text

037 Efficacy and safety of tirabrutinib, highly selective Bruton’s tyrosine kinase inhibitor, for oral treatment of pemphigus: a multicenter, open-label, uncontrolled, single-arm phase 2 study

Journal of Investigative Dermatology ◽

10.1016/j.jid.2021.08.039 ◽

2021 ◽

Vol 141 (10) ◽

pp. S155

Author(s):

J. Yamagami ◽

H. Ujiie ◽

Y. Aoyama ◽

N. Ishii ◽

C. Tateishi ◽

...

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Oral Treatment ◽

Bruton’S Tyrosine Kinase ◽

Phase 2 ◽

Efficacy And Safety ◽

Open Label ◽

Bruton's Tyrosine Kinase ◽

Phase 2 Study

Download Full-text

PULSAR open-label extension: interim results from a phase 2 study of the efficacy and safety of sotatercept when added to standard of care for the treatment of pulmonary arterial hypertension (PAH)

10.1183/13993003.congress-2021.oa140 ◽

2021 ◽

Author(s):

David Badesch ◽

Simon Gibbs ◽

Mardi Gomberg-Maitland ◽

Marius Hoeper ◽

Vallerie Mclaughlin ◽

...

Keyword(s):

Pulmonary Arterial Hypertension ◽

Arterial Hypertension ◽

Standard Of Care ◽

Phase 2 ◽

Efficacy And Safety ◽

Open Label ◽

Phase 2 Study ◽

Open Label Extension ◽

Pulmonary Arterial

Download Full-text

Efficacy and safety of tirabrutinib, highly selective Bruton’s tyrosine kinase inhibitor, for oral treatment of pemphigus: a multicenter, open-label, uncontrolled, single-arm phase 2 study

10.26226/morressier.61081ff8bc981037240fe3ad ◽

2021 ◽

Author(s):

Jun Yamagami

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Oral Treatment ◽

Bruton’S Tyrosine Kinase ◽

Phase 2 ◽

Efficacy And Safety ◽

Open Label ◽

Bruton's Tyrosine Kinase ◽

Phase 2 Study

Download Full-text